23andMe to Report Q4 and Full Year FY2024 Financial Results

Rhea-AI Summary

23andMe Holding Co. (Nasdaq: ME) will announce its financial results for Q4 and FY2024 on May 23, 2024. The company aims to discuss its business progress during a webcast at 4:30 p.m. Eastern Time on the same day. Shareholders can participate in the Q&A session by submitting questions in advance. The webcast link will be available at https://investors.23andme.com/news-events/events-presentations.

Insights

Financial Analyst

The announcement of 23andMe's financial results for Q4 and the full fiscal year is a pivotal event which could influence investor sentiment and future investment decisions. Earnings reports are a direct reflection of a company's performance and strategic direction. Investors should pay close attention to key metrics such as revenue growth, profit margins and earnings per share, as these will indicate how well 23andMe has managed its finances and business operations over the year. Particularly for a biopharmaceutical company, the R&D spending is also an important financial metric, as it can signal ongoing investment in product development and future growth opportunities. Furthermore, any guidance provided for the upcoming fiscal year will be scrutinized for signs of confidence or caution from the company's management. The fact that 23andMe is engaging with its shareholders through the Say Technologies platform for questions ahead of the earnings call reflects a modern approach to corporate transparency and could foster a closer relationship with its investors. The retail investor will want to monitor such a call for insights into the company's performance, especially if they have a stake in the biotechnology or healthcare industry.

Market Research Analyst

The strategic implications of 23andMe's earnings report are potentially wide-ranging. Within the competitive landscape of genomic and biopharmaceutical companies, it's important to assess not only the raw financials but also the subtext regarding product pipeline development, market penetration and any strategic partnerships or acquisitions that may be hinted at during the earnings call. These factors can drive long-term shareholder value. For the retail investor, understanding how 23andMe's developments compare with industry trends and peers is essential. Observing shifts in consumer demand for genetic testing, as well as regulatory impacts on the market, can provide additional context for 23andMe's performance and future prospects. Additionally, the investor community often looks for color on the potential commercialization of any therapeutics in development, which in the case of a company like 23andMe, can prove to be a significant driver of future revenue.

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter and year’s financial results and report on business progress.

The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional shareholders to submit and upvote questions to management in advance of the earnings conference call. Starting today, shareholders can submit questions by visiting https://app.saytechnologies.com/23andme-2024-q4. The Q&A platform will remain open until 24 business hours before the earnings call.

About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, financial projections, funding for continued operations, cash reserves, projected costs, database growth, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

Contacts
Investor Relations Contact: Ian Cooney, ianc@23andme.com
Media Contact: press@23andMe.com

FAQ

When will 23andMe report its Q4 and FY2024 financial results?

23andMe will report its financial results for Q4 and FY2024 on May 23, 2024.

What time will the webcast conference call take place to discuss the financial results?

The webcast conference call to discuss the financial results will be at 4:30 p.m. Eastern Time on May 23, 2024.

How can shareholders access the webcast of the event?

Shareholders can access the webcast of the event on the day of the event at https://investors.23andme.com/news-events/events-presentations.

How can shareholders submit questions to the management in advance of the earnings conference call?

Shareholders can use the Say Technologies platform to submit questions in advance by visiting https://app.saytechnologies.com/23andme-2024-q4.

Until when can shareholders submit questions through the Q&A platform?

Shareholders can submit questions through the Q&A platform until 24 business hours before the earnings call.